Oncology

Ovarian Cancer Patients May Benefit from Novel Immunotherapy

Researchers claim immunotherapy may offer improved outcomes for patients experiencing HRP ovarian cancer.


Novel Monoclonal Antibody Could Transform High-Risk Neuroblastoma Treatment

Researchers at St. Jude Children’s Research Hospital found that adding a novel anti-disialoganglioside GD2 (anti-GD2) monoclonal antibody to the standard therapy for children newly diagnosed with high-risk neuroblastoma significantly enhanced response to treatment and improved survival. Their findings could be transformative if additional studies can produce similar results.


Increased Myocarditis Reported in Patients Receiving Immune Checkpoint Inhibitors

New data indicates patients report myocarditis at higher rates after the use of immune checkpoint inhibitors during cancer treatment.


What Happens When Colorectal Cancer Screening Guidelines Expand?

New guidelines have lowered the recommended starting age for colorectal cancer screening. One expert says clinicians need to do more to increase screening access and compliance while ensuring no patient population is left behind.


Is the CAR T-Cell Revolution Here?

A tailor-made oncology treatment, CAR T-cell therapy promises to transform cancer care. But can its potential overcome its problems?


Could a Multi-Cancer Early Detection Blood Test Signal a Seismic Shift for Cancer Screening?

Galleri, a test developed by California-based healthcare company Grail, can detect dozens of types of cancer — most of which currently lack a recommended screening test — with a single blood sample. What could that mean for the way clinicians screen for and treat cancer?


That’s News

Could Your Oncology Software Get Hacked?

Just as in politics and the energy business, hacking hospital systems is on the rise — and it’s not just patient privacy that’s at risk. In April, a security breach of oncology and radiology system provider Elekta took the radiation systems of numerous...


Who Needs Chemotherapy? For Breast Cancer Patients, the RxPONDER Trial Refines the Answer

Initial results from the Southwest Oncology Group (SWOG) phase 3 RxPONDER trial demonstrate that postmenopausal women with a common form of breast cancer may be able to forego chemotherapy — and its potential adverse effects — in favor of standalone hormone therapy.


Prostate Cancer Care Forges into the Future

Ongoing research offers new promise for patients with metastasized, castration-resistant prostate cancer.


Common Procedure for Gastric Cancer Shows Promise for North American Patients

Endoscopic submucosal dissection was shown to be highly effective at removing superficial gastric tumors and is a viable option for patients around the globe.